1α,25-dihydroxyvitamin D3 modulates human adipocyte metabolism via nongenomic action

被引:181
作者
Shi, H
Norman, AW
Okamura, WH
Sen, A
Zemel, MB
机构
[1] Univ Tennessee, Knoxville, TN 37996 USA
[2] Univ Calif Riverside, Riverside, CA 92521 USA
[3] Zen Bio, Res Triangle Pk, NC USA
关键词
human adipocytes; Ca2+ signaling; lipid metabolism;
D O I
10.1096/fj.01-0584fje
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We reported recently that suppression of the renal 1 alpha ,25-dihyroxyvitamin D-3 (1 alpha ,25-(OH)(2)-D-3) production in aP2-agouti transgenic mice by increasing dietary calcium decreases adiposity. However, it was not clear whether this modulation of adipocyte metabolism by dietary calcium is a direct effect of inhibition of 1 alpha ,25-(OH)(2)-D-3-induced [Ca2+]i. Accordingly, we have now evaluated the direct role of 1 alpha ,25-(OH)(2)-D-3. Human adipocytes exhibited a 1 alpha ,25-(OH)(2)-D-3 dose-responsive (1-50 nM) increase in [Ca2+]i (P<0.01). This action was mimicked by 1<alpha>,25-dihydroxyluministerol(3) (1 alpha ,25-(OH)(2)-lumisterol(3)) (P<0.001), a specific agonist for a putative membrane vitamin D receptor (mVDR), and completely prevented by 1<beta>,25-dihydroxyvitamin D-3 (1 beta ,25-(OH)(2)-D-3), a specific antagonist for the mVDR. Similarly, 1 alpha ,25-(OH)(2)-D-3 (5 mM) caused 50%-100% increases in adipocyte fatty acid synthase (FAS) expression and activity (P<0.02), 61% increase in glycerol-3-phosphate dehydrogenase (GPDH) activity (P<0.01), and an 80% inhibition of isoproterenol-stimulated lipolysis (P<0.001), whereas 1<beta>,25-(OH)(2)-D-3 completely blocked all these effects. Notably, 1 alpha ,25-OH)(2)-lumisterol(3) exerted more potent effects in modulating adipocyte lipid metabolism, with 2.5- to 3.0-fold increases in FAS expression and activity (P<0.001) and a threefold increase in GPDH activity (P<0.001). Also 1 alpha ,25-(OH)(2)-lumisterol3 was approximately twice as potent in inhibiting basal lipolysis (P<0.025), whereas 1<beta>,25-(OH)(2)-D-3 completely blocked all these effects. These data suggest that 1 alpha ,25-(OH)(2)-D-3 modulates adipocyte Ca2+ signaling and, consequently, exerts a coordinated control over lipogenesis and lipolysis. Thus, a direct inhibition of 1 alpha ,25-(OH)(2)-D-3-induced [Ca2+](i) may contribute to an anti-obesity effect of dietary calcium, and the mVDR may represent an important target for obesity.
引用
收藏
页码:2751 / +
页数:15
相关论文
共 44 条
  • [1] Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: Formal histomorphometric and biomechanical analyses
    Amling, M
    Priemel, M
    Holzmann, T
    Chapin, K
    Rueger, JM
    Baron, R
    Demay, MB
    [J]. ENDOCRINOLOGY, 1999, 140 (11) : 4982 - 4987
  • [2] SECONDARY HYPERPARATHYROIDISM OF MORBID-OBESITY REGRESSES DURING WEIGHT-REDUCTION
    ANDERSEN, T
    MCNAIR, P
    HYLDSTRUP, L
    FOGHANDERSEN, N
    NIELSEN, TT
    ASTRUP, A
    TRANSBOL, I
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1988, 37 (05): : 425 - 428
  • [3] BARAN DT, 1991, J BONE MINER RES, V6, P1269
  • [4] Baran DT, 2000, J CELL BIOCHEM, V78, P34, DOI 10.1002/(SICI)1097-4644(20000701)78:1<34::AID-JCB4>3.3.CO
  • [5] 2-Q
  • [6] BELL NH, 1988, J BONE MINER RES, V3, P489
  • [7] EVIDENCE FOR ALTERATION OF THE VITAMIN-D-ENDOCRINE SYSTEM IN OBESE SUBJECTS
    BELL, NH
    EPSTEIN, S
    GREENE, A
    SHARY, J
    OEXMANN, MJ
    SHAW, S
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (01) : 370 - 373
  • [8] A SIMPLE ONE-STEP ENZYMATIC FLUOROMETRIC METHOD FOR THE DETERMINATION OF GLYCEROL IN 20-MU-1 OF PLASMA
    BOOBIS, LH
    MAUGHAN, RJ
    [J]. CLINICA CHIMICA ACTA, 1983, 132 (02) : 173 - 179
  • [9] STRUCTURE-FUNCTION-RELATIONSHIPS IN THE VITAMIN-D ENDOCRINE SYSTEM
    BOUILLON, R
    OKAMURA, WH
    NORMAN, AW
    [J]. ENDOCRINE REVIEWS, 1995, 16 (02) : 200 - 257
  • [10] CYTOSOLIC CALCIUM AND INSULIN RESISTANCE IN ELDERLY PATIENTS WITH ESSENTIAL-HYPERTENSION
    BYYNY, RL
    LOVERDE, M
    LLOYD, S
    MITCHELL, W
    DRAZNIN, B
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1992, 5 (07) : 459 - 464